Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Topotecan and Paclitaxel with Filgrastim in Extensive-Stage SCLC
NCT00004055Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 1999
- Primary completion
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan and paclitaxel in small cell lung cancer (SCLC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Complete and Partial Response Rate up to 6 months. Started Nov 1999; status: completed.
02
Drugs
topotecanpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00004055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004055.